Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

Response and survival, trial by trial.

Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.

18 arms have a reported figure in this set.

Avapritinib 4

Avapritinib

Avapritinib 300 or 400 mg, PDGFRA exon 18

300 or 400 mg · Single arm

unresectable or metastatic GIST with PDGFRA exon 18 mutation (n = 43)

overall response rate (independent review): 84%, median follow up 10.6 months

NAVIGATOR · NCT02508532

Avapritinib

Avapritinib, PDGFRA D842V subgroup

300 or 400 mg · Single arm

PDGFRA D842V (n = 38)

overall response rate (independent review): 89%, median follow up 10.6 months

NAVIGATOR · NCT02508532

Avapritinib

Avapritinib 300 mg

300 mg · ITT

3L or later GIST (n = 240)

Comparator: regorafenib 160 mg

objective response rate: 17.1%, primary analysis

VOYAGER · NCT03465722

Avapritinib

Regorafenib 160 mg

160 mg · ITT

3L or later GIST (n = 236)

objective response rate: 7.2%, primary analysis

VOYAGER · NCT03465722

Bezuclastinib + Sunitinib 2

Bezuclastinib + Sunitinib

Bezuclastinib 600 mg + sunitinib 37.5 mg

600 mg + 37.5 mg · ITT

GIST after imatinib (n = 204)

Comparator: sunitinib 37.5 mg

objective response rate (BICR): 46%, data cutoff 09.30.2025

Peak · NCT05208047

Bezuclastinib + Sunitinib

Sunitinib 37.5 mg continuous

37.5 mg · ITT

GIST after imatinib (n = 209)

objective response rate (BICR): 26%, data cutoff 09.30.2025

Peak · NCT05208047

Imatinib 3

Imatinib

Imatinib 400 mg

400 mg · ITT

KIT (CD117) positive unresectable or metastatic GIST

Comparator: imatinib 600 mg

objective response rate (SWOG): 68.5%, up to 36 months

Imatinib Phase 2 (400 vs 600 mg)

Imatinib

Imatinib 600 mg

600 mg · ITT

KIT (CD117) positive unresectable or metastatic GIST

Comparator: imatinib 400 mg

objective response rate (SWOG): 67.6%, up to 36 months

Imatinib Phase 2 (400 vs 600 mg)

NB003 2

NB003

NB003, 2L to 4L or later

not stated in source · Single arm

GIST 2L to 4L or later (n = 158)

objective response rate: 28.5%, data as of March 2025

NB003 Phase 1 · NCT04936178

NB003

NB003, 3L subgroup

not stated in source · Single arm

GIST 3L (n not stated in source)

objective response rate: 46.7%, data as of March 2025

NB003 Phase 1 · NCT04936178

Olverembatinib (HQP1351) 1

Olverembatinib (HQP1351)

Olverembatinib 30 to 50 mg every other day

30 to 50 mg · Single arm

SDH-deficient GIST (n = 26)

partial response as best response: 23.1%, cutoff 11.13.2025

HQP1351SJ0003 · NCT03594422

Ripretinib 3

Ripretinib

Ripretinib 150 mg

150 mg · ITT

GIST after imatinib, sunitinib and regorafenib

Comparator: placebo

objective response rate (BICR): 9%, primary analysis

INVICTUS · NCT03353753

Ripretinib

Ripretinib 150 mg

150 mg · ITT

GIST after imatinib (ITT n = 226)

Comparator: sunitinib 50 mg 4/2

objective response rate, KIT exon 11 ITT: 23.9%, primary analysis; nominal P = .03

INTRIGUE · NCT03673501

Ripretinib

Sunitinib 50 mg 4/2

50 mg · ITT

GIST after imatinib (ITT n = 227)

objective response rate, KIT exon 11 ITT: 14.6%, primary analysis

INTRIGUE · NCT03673501

Sunitinib 1

Sunitinib

Sunitinib 50 mg, 4 weeks on 2 off

50 mg · ITT

GIST after imatinib progression or intolerance

Comparator: placebo

objective response rate (partial responses): 6.8%, interim analysis

Study 1 · NCT00075218

Velzatinib (IDRX-42, GSK6042981) 2

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.